LONDON--(BUSINESS WIRE)--Technavio’s latest report on the global infantile spasms therapeutics market provides an analysis of the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.
Sapna Jha, a lead analyst from Technavio, specializing in research on cardiovascular and metabolic disorders sector, says, “The global infantile spasms therapeutics market is growing at a slow pace. This is due to the increased availability of generic drugs and less approved therapies in the market and the less awareness of the disease and the available treatment options, especially in the low- and middle-income countries.”
Orphan designation of drugs by the European Medicines Agency (EMA) and the US FDA makes them eligible for incentives such as tax credits for qualified clinical testing, exemption from prescription drug user fees unless indicated for additional non-orphan indications and market exclusivity for seven years in the US and ten years in the EU. High unmet medical needs regarding the development of drugs that have a high safety and efficacy profile and patient assistance programs, in terms of reimbursements, offered by various governmental and non-governmental organizations propel the growth of the market.
Request a sample report: http://www.technavio.com/request-a-sample?report=55538
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
The top three emerging trends driving the global infantile spasms therapeutics market according to Technavio healthcare and life sciences research analysts are:
- Development of devices and smartphone apps to detect seizures and track medications
- Alternate drugs fill the gap
- Reformulation of marketed drugs
Development of devices and smartphone apps to detect seizures and track medications
The new trend observed in the infantile spasms market is the development of seizure alert devices that detects the seizure and notifies it to the physician, through alarms, phone calls, or text messages. SmartMonitor has developed a watch, SmartWatch, which should be worn 24 hours a day to detect any seizures. If it detects any seizures, it immediately sends out an alert warning to the caregivers/physicians. The device is now available only in the US.
“Empatica has developed another smart watch, Embrace, which monitors the physiological stress, arousal, sleep, and physical activity of the individual. Apart from this, a smartphone application EpDetect has been developed, which exploits advanced signal processing to detect seizures,” according to Sapna.
Alternate drugs fill the gap
Considering there is a lack of exact therapy targeted at complete remission of infantile spasms, the alternative drugs are used extensively by the individuals. The available drugs such as adrenocorticotropic hormone (ACTH), vigabatrin, and oral corticosteroids fail to induce complete cessation of infantile spasms are ideally a threat to market growth. In the absence of any proven remission track, alternative drugs come quite helpful to fuel the drug sales for infantile spasms market.
Prednisone is approved for the treatment of inflammatory diseases and autoimmune disease, but this medication is also used for the treatment of infantile spasms market. Similarly, other alternative treatments such as nitrazepam, valproic acid, topiramate, levetiracetam, lamotrigine, felbamate, and ganaxolone are also available for the treatment of infantile spasms.
Reformulation of marketed drugs
Drug delivery systems such as film-coated tablets and dispersible increase the efficacy of drugs either by increasing the bioavailability or by expanding the compliance of an individual. This reformulation results in products with improved efficacy and safety profiles and provides an opportunity for drug makers to extend the term of their drug patents delaying the market entry of generic drug. For instance, Pfizer, UCB, and GlaxoSmithKline developed film-coated tablets of Neurontin, Keppra, and Trobalt, respectively.
The key vendors are as follows:
- H. Lundbeck
- INSYS Therapeutics
- Mallinckrodt Pharmaceuticals
Browse Related Reports:
- Global Multiple Myeloma Drugs Market 2017-2021
- Global Cancer Monoclonal Antibodies Market 2017-2021
- Global Artificial Pancreas Devices System Market 2016-2020
Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like in-vitro diagnostics, urology devices, and vaccines. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.
About Technavio
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at media@technavio.com.
